首页> 外文期刊>癌と化学療法 >Chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for oral cancer
【24h】

Chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for oral cancer

机译:用腹皮胰蛋白的超级化鼻腔内输注化疗与口腔癌放射治疗

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nedaplatin (CDGP), which is a CDDP derivative, has been reported to be an effective anticancer agent for head and neck cancer. This study was performed to assess the feasibility of chemotherapy by superselective intraarterial infusion of nedaplatin (CDGP) in patients with oral cancers. Ten patients were treated with chemotherapy by superselective intraarterial infusion of CDGP combined with radiotherapy. The complete and partial response rates were 7/10 (70%) and 3/10 (30%), respectively. Nine patients showed grade 1-2 hematological toxicity including leukocytopenia and anemia. Thrombocytopenia of grade 4 was seen in only one patient. However, all the patients were free from renal dysfunction. From these results, it is suggested that this combination therapy might be quite effective and safe. Further study will be needed to determine its efficacy against oral cancer.
机译:据报道,作为CDDP衍生物的Nedaplatin(CDGP)是头部和颈部癌症的有效抗癌剂。 本研究进行了口服癌症患者的腹膜铂(CDGP)的超重血液插管化疗的可行性。 通过CDGP的超重鼻内输注与放射治疗进行化学治疗10名患者。 完整和部分反应率分别为7/10(70%)和3/10(30%)。 九名患者显示1-2级血液毒性,包括白细胞减少症和贫血。 4级的血小板减少只在一个患者中看到。 然而,所有患者都没有肾功能紊乱。 从这些结果来看,建议这种联合治疗可能非常有效和安全。 需要进一步研究以确定其对口腔癌的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号